Alzheimer's Drug Approved by Health Canada
Lecanemab, a lab-made antibody, aims to slow the early stages of Alzheimer's disease by targeting plaques in the brain.
According to the Alzheimer Society of Canada, lecanemab is the first disease-modifying Alzheimer's treatment approved for use in the country.
- Given by intravenous infusion
- Targets the buildup of amyloid plaque in the brain
- Not a cure and cannot reverse the disease or restore lost memories
Lecanemab is the first disease-modifying Alzheimer's treatment approved for use in Canada.
The conditional approval of lecanemab is being called a positive development for those diagnosed with dementia.
Author's summary: Lecanemab approved in Canada to slow Alzheimer's.
More News
- The unexpected reaction of Tyreek Hill after the firing of Dolphins general manager Chris Grier
- Pras Michel Must Forfeit $64 Million After Criminal Convictions in Foreign Influence Case
- A.J. Brown, other injured Eagles have a crucial 15 days to recover thanks to bye week
- Stephen A. Smith Questions Why Chris Grier Got Fired Before Mike McDaniel After Dolphins' Embarrassing Loss
- No Giannis, No Problem — Bucks Take Down Warriors as Antetokounmpo Steals the Show in Minion Costume
- Bam Adebayo's evolution into 'three-level scorer' starts with Heat's new offense
- Why Ryan Rollins loved Draymond Green coming for him after Stephen Curry incident
- Bose headphones and earbuds return to all-time lows for Black Friday